Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
381.32(c) 381.72(c) 386.67(c) 383.12(c) 388.95(c) Last
517 973 456 416 570 570 425 056 1 271 176 Volume
+0.14% +0.10% +1.30% -0.92% +1.52% Change
More quotes
Financials ($)
Sales 2017 5 764 M
EBIT 2017 2 451 M
Net income 2017 1 480 M
Finance 2017 2 285 M
Yield 2017 -
Sales 2018 6 234 M
EBIT 2018 2 706 M
Net income 2018 1 609 M
Finance 2018 4 017 M
Yield 2018 -
P/E ratio 2017 31,13
P/E ratio 2018 28,84
EV / Sales2017 6,85x
EV / Sales2018 6,06x
Capitalization 41 789 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in inventing medicines for people with serious diseases.It includes Arcalyst, Dupixent, Eylea, Kevzara, and Praluent injections.The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M.... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
07:01a REGENERON PHARMACEUTICALS : and ISA Pharmaceuticals Announce Strategic Immuno-On..
12/15 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Topline Pivotal Results..
12/15 REGENERON PHARMACEUTICALS : Collaboration Programs Highlighted During Sanofi Ana..
12/14 REGENERON PHARMACEUTICALS : Investigators from Regeneron Pharmaceuticals Inc. Ha..
12/14 SANOFI : details R&D strategy, reports cSCC data for PD-1 inhibitor
12/13 France's Sanofi pins hopes on new drugs after setbacks
12/13 REGENERON PHARMACEUTICALS : Announces FDA Acceptance of sBLA Filing for 12-Week ..
12/13 Celgene, Gilead, and Regeneron are On the Mend
12/13 REGENERON PHARMACEUTICALS : Collaboration Programs Highlighted During Sanofi Ana..
12/13 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Topline Pivotal Results..
More news
Sector news : Bio Therapeutic Drugs
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15DJALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
12/13 France's Sanofi pins hopes on new drugs after setbacks
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on REGENERON PHARMACEUTICALS 
REGENERON PHARMACEUTICALS - 09/19
A long term support level to be taken advantage of
BUY
REGENERON PHARMACEUTICALS - 08/21
One can take advantage of the trading range to enter new positions
BUY
More Strategies
News from SeekingAlpha
12/17 YOUR DAILY PHARMA SCOOP : Aclaris Gets Approval, Egalet Surges, Alnylam Gains As..
12/15 Buy Regeneron - Cramer's Lightning Round (12/14/17)
12/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 14, 2017
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/13 Regeneron updates investors on collaboration programs with Sanofi
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 457 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS5.95%41 789
GILEAD SCIENCES6.94%98 689
VERTEX PHARMACEUTICALS96.55%36 888
GENMAB-11.85%9 967
BLUEBIRD BIO INC199.68%8 385
EXELIXIS, INC.78.27%7 722